
    
      This study will evaluate the efficacy and safety of TAK-475 (lapaquistat acetate) compared to
      placebo in subjects with primary hypercholesterolemia. Subjects who have signed the informed
      consent will undergo necessary evaluations to determine eligibility for a dietary run-in
      phase. Subjects who meet randomization criteria will enter treatment with one of the
      following randomized treatments: lapaquistat acetate or placebo.
    
  